Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.

Lymph node involvement may help predict metastases in breast cancer

3 days ago

Future development of distant metastases can be accurately predicted by combining primary tumour and stromal features with the histopathological patterns of involved and uninvolved lymph nodes (LN), a recent study has found.

Using the haematoxylin- and eosin-stained sections of 309 invasive breast carcinoma patients (median age 55 years), researchers characterized both the primary tumours and the axillary LNs. Multivariate proportional hazard regression was used to determine the sets of covariates that had the most accurate prediction of distant metastasis-free survival (DMFS).

Combining clinicopathological with histological features increases the accuracy in predicting 5-year DMFS. In all patients included, the combined covariates correctly predicted 5-year DMFS in 71 percent of the patients, as opposed to 68 and 62 percent of the patients when using only either set of features, respectively. In both sets of features, LN status and features were included.

In comparison, patients with triple-negative breast cancer (TNBC), histological features had higher accuracy than clinicopathological features (71 vs 67 percent) in predicting 5-year DMFS. The combined set of features still returned the highest accuracy.

In patients with LN involvement, incorporating five histological features (Salgado’s classification, size and number of germinal centres [GC] in uninvolved LN, location of GCs in involved LNs, and the presence of lymphocytic lobulitis) improved the predictive accuracy in all cancer patients and in TNBC patients.

Specifically, accuracy improved from 50 percent baseline performance to 64 percent in all breast cancer patients, and from 58 percent at baseline to 74 percent in TNBC patients. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.